KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Operating Expenses (2017 - 2025)

Bionano Genomics' Operating Expenses history spans 7 years, with the latest figure at $11.9 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 66.41% year-over-year to $11.9 million; the TTM value through Sep 2025 reached $49.9 million, down 57.09%, while the annual FY2024 figure was $104.4 million, 53.58% down from the prior year.
  • Operating Expenses for Q3 2025 was $11.9 million at Bionano Genomics, up from $11.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $116.0 million in Q3 2023 and bottomed at $11.3 million in Q2 2025.
  • The 5-year median for Operating Expenses is $29.0 million (2021), against an average of $30.7 million.
  • The largest annual shift saw Operating Expenses skyrocketed 241.48% in 2023 before it crashed 69.42% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $29.0 million in 2021, then skyrocketed by 35.52% to $39.3 million in 2022, then tumbled by 30.36% to $27.4 million in 2023, then plummeted by 43.93% to $15.4 million in 2024, then dropped by 22.44% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Operating Expenses are $11.9 million (Q3 2025), $11.3 million (Q2 2025), and $11.4 million (Q1 2025).